BDTX bets on silevertinib's broad EGFR mutation reach and CNS activity, but with no approved products, upcoming 2026 data and partnerships are pivotal Key Takeaways BDTX centers its strategy on silevertinib, its only clinical asset in EGFR-mutant NSCLC.Silevertinib shows 60%...
Abstract Non-small cell lung cancer (NSCLC) is the most prevalent subtype of lung cancer, with persistently low overall cure and survival rates, largely attributed to tumor immune escape. This study aims to explore the role of RBM15 in the immune...
Liquid biopsy, particularly cerebrospinal fluid analysis, plays a key role in managing brain metastasis in EGFR-mutant NSCLC. This review highlights its superior ability to detect CNS-specific resist 1 Background Advancements in precision medicine have led to earlier diagnoses of lung...
AbstractBackground and Objective The cytochrome P450 (CYP) system plays a central role in drug metabolism and pharmacokinetic variability, influencing drug–drug interaction risk. The newly synthesized 4-propoxy-2-arylquinoline derivatives (MW1–3) are dual inhibitors of epidermal growth factor receptor (EGFR) and focal adhesion...
Resistance to anti-EGFR therapy remains a major challenge in head and neck squamous cell carcinoma (HNSCC), as adaptive mechanisms driven by drug-tolerant persister cells (DTPs) ultimately compromise treatment efficacy. Here, we identify Interleukin-1 (IL-1)-mediated inflammation as a critical driver of...
VIDEO: Osimertinib plus chemotherapy improves PFS in NSCLC with EGFR, TP53 mutations COPENHAGEN, Denmark - In this Healio video, Alissa J. Cooper, MD, a thoracic oncologist at Dana-Farber Cancer Institute, discusses the TOP trial of osimertinib plus chemotherapy in high-risk...
AbstractPurpose of Review This review examines the mechanisms of acquired resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). While genetic bypass mutations are well-understood, the focus here is on lineage plasticity-a non-genetic process where...
Background Leptomeningeal metastasis (LM) after the development of third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance is indicative of a poor prognosis in EGFR-mutant non-small cell lung cancer (NSCLC), and no standardised treatments are currently available. The aims...
Open AccessReview Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression by Nuri ParkNuri Park SciProfiles Scilit Preprints.org Google Scholar 1,2,†, Yejin ChoYejin Cho SciProfiles Scilit Preprints.org Google Scholar 1,†, Hong-Mei ZhengHong-Mei Zheng SciProfiles Scilit Preprints.org...
